Surgery: Clinical Research

[Return to search results]

Clinical Trial Details

Bay 59-7939/17454: An International, Multicenter, Randomized, Double-Blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients with Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures. VOYAGER PAD
Study Purpose
The purpose of this study is to find out about the safety and efficacy of rivaroxaban combined with aspirin in reducing the risk of major cardiovascular events (such as stroke or heart attack) after a person with vessel disease in their legs has had a revascularization procedure to improve blood flow.
Study Plan
Patients who qualify for this study will be assigned by chance (like the flip of a coin) to get one of the following treatments: • Treatment 1: Rivaroxaban 2.5mg tablet twice per day plus aspirin 100mg tablet once per day. • Treatment 2: Placebo tablet twice per day plus aspirin 100mg tablet once per day.
Open Enrollment
Contact Name: Andrea Goosen
Contact Phone: 904-244-5632

Principal Investigator
Daniel Soffer, M.D.

Sub Investigator
John Pirris, M.D.